Kamada Ltd. develops, produces, and markets plasma-derived protein therapeutics for orphan indications. It operates through two segments, Proprietary Products and Distribution. The company offers respiratory products, including Glassia for use in augmentation and maintenance therapy in adults with emphysema due to congenital Alpha-1 Antitrypsin (AAT) deficiency.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone972-8940-6472
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$114.47 million
Profitability
Miscellaneous
Employees408
Next Earnings Date11/11/2019 (Estimated)
OptionableNot Optionable
Kamada (NASDAQ:KMDA) Frequently Asked Questions
What is Kamada's stock symbol?
Kamada trades on the NASDAQ under the ticker symbol "KMDA."
How were Kamada's earnings last quarter?
Kamada Ltd. (NASDAQ:KMDA) announced its quarterly earnings results on Tuesday, August, 6th. The biotechnology company reported $0.15 EPS for the quarter, beating the Zacks' consensus estimate of $0.14 by $0.01. The biotechnology company earned $35.25 million during the quarter, compared to the consensus estimate of $33.86 million. Kamada had a net margin of 21.10% and a return on equity of 23.60%. View Kamada's Earnings History.
When is Kamada's next earnings date?
What guidance has Kamada issued on next quarter's earnings?
Kamada issued an update on its FY 2019 earnings guidance on Tuesday, August, 6th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $125-130 million, compared to the consensus revenue estimate of $128.49 million.
What price target have analysts set for KMDA?
2 equities research analysts have issued 1-year price targets for Kamada's stock. Their forecasts range from $7.00 to $11.00. On average, they anticipate Kamada's share price to reach $9.00 in the next twelve months. This suggests a possible upside of 75.4% from the stock's current price. View Analyst Price Targets for Kamada.
What is the consensus analysts' recommendation for Kamada?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kamada in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Kamada.
What are Wall Street analysts saying about Kamada stock?
Here are some recent quotes from research analysts about Kamada stock:
- 1. According to Zacks Investment Research, "Kamada Ltd. is a biopharmaceutical company. It develops, produces and markets therapeutics based on chromatographic purification technology. The company offers bio-therapeutics for specialty proteins, specific immunoglobulins and other prescription medicines. Kamada Ltd. is headquartered in Ness Ziona, Israel. " (8/13/2019)
- 2. HC Wainwright analysts commented, "Our price target of $11/share is based on an equally weighted composite of: (a) $14.26/share, as a 35x multiple of taxed and diluted FY23 GAAP EPS of $0.84 discounted back to and (b) an NPV of $8.1/share (discount rate 12%, growth rate 2%). Risks to our investment thesis and target price include: (1) failure of AAT (IV and IH) to achieve peak commercial revenue estimates in our model (due to market size, penetration rates, and/ or pricing); (2) failure of IH-AAT in clinical studies; (3) failure of IH-AAT to secure regulatory approval; and (4) other potential pipeline failures." (8/7/2019)
Has Kamada been receiving favorable news coverage?
News stories about KMDA stock have been trending negative this week, according to InfoTrie Sentiment Analysis. The research group rates the sentiment of media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Kamada earned a media sentiment score of -2.9 on InfoTrie's scale. They also assigned press coverage about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the stock's share price in the next several days. View News Stories for Kamada.
Are investors shorting Kamada?
Kamada saw a decline in short interest during the month of August. As of August 31st, there was short interest totalling 13,700 shares, a decline of 20.8% from the July 31st total of 17,300 shares. Based on an average trading volume of 37,800 shares, the short-interest ratio is currently 0.4 days. Approximately 0.1% of the shares of the company are short sold. View Kamada's Current Options Chain.
Who are some of Kamada's key competitors?
Some companies that are related to Kamada include Rhythm Pharmaceuticals (RYTM), Principia Biopharma (PRNB), Emisphere Technologies (EMIS), Eagle Pharmaceuticals (EGRX), Cytokinetics (CYTK), Stoke Therapeutics (STOK), CannTrust (CNTTF), Advanz Pharma (CXRXF), ZEALAND PHARMA/S (ZEAL), Kura Oncology (KURA), Karyopharm Therapeutics (KPTI), ZIOPHARM Oncology (ZIOP), Vanda Pharmaceuticals (VNDA), Rocket Pharmaceuticals (RCKT) and Capstone Therapeutics (CAPS).
What other stocks do shareholders of Kamada own?
Who are Kamada's key executives?
Kamada's management team includes the folowing people:
- Mr. Amir London, Chief Exec. Officer (Age 50)
- Mr. Chaime Orlev, Chief Financial Officer (Age 49)
- Mr. Eran Nir, VP of Operations & Plant Mang. (Age 46)
- Mr. David Tsur, Co-Founder & Active Deputy Chairman (Age 68)
- Dr. Naveh Tov M.D., Ph.D., VP of Clinical Devel. & Medical Director for Pulmonary Diseases (Age 55)
Who are Kamada's major shareholders?
Kamada's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Delek Group Ltd. (2.50%), Acadian Asset Management LLC (2.44%), Renaissance Technologies LLC (1.99%), Ibex Investors LLC (0.68%), Marshall Wace LLP (0.20%) and ARK Investment Management LLC (0.20%).
Which institutional investors are selling Kamada stock?
KMDA stock was sold by a variety of institutional investors in the last quarter, including Ibex Investors LLC and ARK Investment Management LLC.
Which institutional investors are buying Kamada stock?
KMDA stock was purchased by a variety of institutional investors in the last quarter, including Delek Group Ltd., Renaissance Technologies LLC, Jane Street Group LLC, BlackRock Inc., Acadian Asset Management LLC, Engine Capital Management LP, Marshall Wace LLP and C M Bidwell & Associates Ltd..
How do I buy shares of Kamada?
Shares of KMDA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Kamada's stock price today?
One share of KMDA stock can currently be purchased for approximately $5.13.
How big of a company is Kamada?
Kamada has a market capitalization of $206.53 million and generates $114.47 million in revenue each year. The biotechnology company earns $22.30 million in net income (profit) each year or $0.55 on an earnings per share basis. Kamada employs 408 workers across the globe.View Additional Information About Kamada.
What is Kamada's official website?
How can I contact Kamada?
Kamada's mailing address is 2 HOLTZMAN ST. SCIENCE PARK, REHOVOT L3, 7670402. The biotechnology company can be reached via phone at 972-8940-6472 or via email at [email protected]
MarketBeat Community Rating for Kamada (NASDAQ KMDA)
MarketBeat's community ratings are surveys of what our community members think about Kamada and other stocks. Vote "Outperform" if you believe KMDA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KMDA will underperform the S&P 500 over the long term. You may vote once every thirty days.
